Cyprinid herpesvirus-3 (CyHV-3) is an etiological agent of a notifiable disease that causes high mortality rates (80--100%) affecting both the common and koi carp *Cyprinus carpio* L. ([@bib0100; @bib0105]). Outbreaks of this virus were reported in Europe ([@bib0035]), US and Israel ([@bib0100]), as well as in South East Asia ([@bib0185; @bib0130; @bib0095]). Two different prophylactic strategies have been developed for protection against CyHV-3: (1) a brief exposure to the virus, followed by transferring infected fish to non-permissive temperature (30 °C) or (2) infection with a live attenuated CyHV-3 ([@bib0170; @bib0160]). However, recent studies indicate that survivors of CyHV-3 infection can become carriers for the disease ([@bib0210; @bib0025; @bib0055]). There is no current treatment for CyHV-3 infected fish.

RNA mediated interference (RNAi) is an emerging strategy used for understanding gene function and is a promising method in developing novel therapeutics and antiviral medications ([@bib0070]). RNAi based therapeutics have been suggested for the development of novel therapies against viral diseases and parasitic agents of aquatic organisms ([@bib0135]). Recent *in vitro* ([@bib0190]) and *in vivo* ([@bib0195]) studies have demonstrated promising results for using RNAi to combat white spot syndrome virus (WSSV), which is an aquatic viral disease of shrimp. Similarly, several *in vitro* ([@bib0180; @bib0125; @bib0120]) and *in vivo* ([@bib0205; @bib0200; @bib0030]) studies have tested controlling a fish viral disease, termed viral hemorrhagic septicemia virus (VHSV), by RNAi. For this study, the feasibility of using short double stranded RNAs termed small interfering (si)RNAs was tested to inhibit *in vitro* viral replication of CyHV-3. The siRNAs target either thymidine kinase (TK) or DNA polymerase (DP) genes, which both code for transcripts involved in DNA replication and are regulated differentially when CyHV-3 infected common carp brain (CCB) cells are subjected to non-permissive temperature ([@bib0045]).

A new primer set was designed to measure the release of CyHV-3 from infected cells based on a component of the viral envelope (glycoprotein ORF81), one of the earliest characterized CyHV-3 proteins ([@bib0175]). The 771 bp coding sequence of CyHV-3 ORF81, GenBank access number [JQ308818.1](ncbi-n:JQ308818.1){#intr0025}, Gene ID: 382929299 was cloned into pET100 (Life Technologies, Wien, Austria). The vector was digested with ScaI (Promega, Wien, Austria) and subjected to a series of 10-fold dilutions starting with 1 ng/μl of plasmid DNA. A standard curve for a primer set targeting ORF81 ([Table 1](#tbl0005){ref-type="table"}A) was tested for detection of CyHV-3 by TaqMan hydrolysis quantitative (qPCR) and showed the primers to be efficient for quantitation of the virus ([Fig. 1](#fig0005){ref-type="fig"}). The siRNAs to target CyHV-3-U thymidine kinase gene, GenBank access number [AB375385.1](ncbi-n:AB375385.1){#intr0030}, Gene ID: 241661587 and DNA polymerase gene, GenBank access number [AY939862.1](ncbi-n:AY939862.1){#intr0035}, Gene ID: 61696088 were designed using Block-iT RNAi Designer (Invitrogen, Wien, Austria), and synthesized by Ambion (Invitrogen) to carry dTdT 3′ overhangs ([Table 1](#tbl0005){ref-type="table"}B). In addition, siRNAs targeting non-CyHV-3 genes, but a gene in spring viremia of carp virus (SVCV) was used as a control ([Table 1](#tbl0005){ref-type="table"}C). Duplexes were resuspended in DEPC-treated water to obtain 20 μM (0.266 μg/μl) solutions and aliquoted for use.

CCB-816 cells were propagated in ZB4G medium: MEM Earle\'s salts 880 ml/L (Invitrogen), [l]{.smallcaps}-Glutamine 200 mM (Invitrogen) 10 ml/L, Gibco non-essential amino acids 10 ml/L (Invitrogen), with 10% per volume fetal bovine serum (FBS) and antibiotic/antimycotic mix (Sigma--Aldrich, Vienna, Austria). Two days after seeding CCB cells into fresh 24-well plates, a 100 μl aliquot of CyHV-3 at 10^3.39^ TCID~50~/ml was added to each plate and incubated at 22 °C. The next day, siRNA aliquots were added according to the manufacturer\'s instructions into duplicate wells in the previously prepared 24-well plate. Briefly, siRNA aliquots were resuspended in 100 μl opti-mem^®^ I reduced-serum medium liquid (Invitrogen) and incubated with 1 μl Lipofectaimine^®^ LTX reagent (Invitrogen) at room temperature for 30 min and appropriate aliquots were applied immediately into individual wells. On the next day, 24 h post addition of siRNAs, the medium was replaced. Six days later, the medium from each plate was collected to be used for quantitation of viral release by qPCR. DNA was extracted from 200 μl supernatant fractions using the DNeasy Blood and Tissue kit (Qiagen, Hilden, Germany). DNA expression was measured in duplicates using qPCR using the CFX real-time system attached to a C100 Touch thermal cycler (Bio-Rad, Vienna, Austria). For treatment with siRNAs targeting CyHV-3, except for treatment with 3 μl TK, there was a correlative effect for the quantity of siRNA treatment targeting either TK or DP and reduction of viral release as measured by qPCR compared to control siRNAs ([Fig. 2](#fig0010){ref-type="fig"}). Treatment with a final concentration of 60 nM (3 μl) of siRNAs targeting DP was more effective at reducing virus release than the equivalent treatment targeting TK (3 μl), or a cumulative final concentration for both siRNAS of 60 nM provided by treatment with 1.5 μl DP and 1.5 μl TK ([Fig. 2](#fig0010){ref-type="fig"}d).

The 295 kb genome of CyHV-3 codes for 156 open reading frames ([@bib0015]) and the relative transcriptional timing for each gene has been annotated ([@bib0110]). [@bib0140] have elucidated 40 of the CyHV-3 proteins incorporated into mature virons. Several recent studies addressed the host--pathogen interactions of CyHV-3 on the protein level ([@bib0085; @bib0090; @bib0155]) or on the transcriptional level ([@bib0005; @bib0010; @bib0165]). Infectious CyHV-3 material remains persistent in the natural environmental ([@bib0145]) and factors such as feeding ([@bib0115]), mating ([@bib0215]) or high stocking density ([@bib0050]) exacerbate conditions for CyHV-3 outbreaks. The only currently acceptable measure for the control of CyHV-3 outbreaks is depopulation (eradication of the infected and exposed fish) and disinfection of all materials and systems that have been in contact with infected fish. The purpose of this study was to test the feasibility of using RNAi as an alternative strategy to save CyHV-3 infected fish. The machinery for RNAi is presumed to have developed naturally as a defensive mechanism against viruses and transposable elements ([@bib0150]). [@bib0060] first demonstrated that the RNAi pathway is induced by double stranded RNA. In this study, short double stranded RNA that targets CyHV-3 genes involved in DNA synthesis was tested to inhibit viral release in CCB cells.

Earlier PCR protocols for detection ([@bib0075; @bib0020]) or quantitation ([@bib0080; @bib0220]) of CyHV-3 were developed based on the amplification of regions that either lacked a biologically defined function or on the TK gene. For this study, a new qPCR protocol was developed to measure the release of viral particles from CCB infected cells for a gene (ORF81) with a biologically defined function which was not targeted by the siRNA. Previous findings in TK deletions reported no significant differences for *in vitro* replication of CyHV-3 compared to wild-type virus ([@bib0040; @bib0065]). However, differences in mortality rates were observed in the CyHV-3 TK deletion strain during an *in vivo* trial ([@bib0040]). The disparity from those trials can lead one to speculate that although attenuation of CyHV-3 in the TK deletion strain can be observed *in vivo* by lower mortality rates, it may have been overlooked *in vitro* because both aforementioned studies measured virus titer by endpoint titration. In this study, viral replication was measured by qPCR, which is a sensitive quantitation tool that recognizes fine difference in copy number. In our study we were able to observe differences of viral particle release by siRNA inhibition of both TK and DP as compared to control siRNA in CyHV-3 infected CCB cells. The subtle differences detected by qPCR may explain differential *in vivo* survival rates observed in TK deletions ([@bib0040]). The siRNAs used in this trial were unmodified and are known to be effective for a limited time after transfection ([@bib0200]). The transient nature of siRNA inhibition can be enhanced by chemical modifications to siRNAs ([@bib0200]) or the use of longer dsRNA (27/25 mer) that are cellular substrate targets for dicer ([@bib0030]).

For this study, siRNA was designed to target two genes involved in DNA replication (TK and DP) and the inhibition of viral replication caused by the siRNAs was measured by a reporter gene (ORF81) all of which are considered early genes that are transcribed in the first 2--4 h after CyHV-3 infection in CCB cells ([@bib0110]). Although the statistical significance was not explicitly calculated for the effectiveness of each siRNA, experiments performed in triplicate showed that treatment with siRNA targeting either TK or DP genes significantly reduced the release of viral particles from infected CCB cells ([Fig. 2](#fig0010){ref-type="fig"}). However, siRNA targeting DP was most effective at reducing viral release as measured by qPCR of ORF81. This preliminary trial with siRNA establishes the basis for using RNAi technology, preferably more stable forms such as long dsRNA that target the entire DP transcript, to control CyHV-3. Further *in vivo* trials should be performed to determine whether RNAi-based therapeutics can be used to protect fish from CyHV-3.
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![Standard curve for quantitation of ORF81. (A) TaqMan hydrolysis qPCR primer set targeting ORF81 was established for quantitation of the CyHV-3. (B) The dilution series begins with the equivalent of 7.10 × 10^8^ viral particles which is detected below the 13th curve threshold (Cq) and ends with the equivalent of 7.10 × 10^0^ viral particles which is detected near the 40th Cq. The final dilution lacks a duplicate, indicated by \#.](gr1){#fig0005}

![Inhibition of viral replication. For figures (A--D), Taqman qPCR was used to measure the inhibition of viral replication. The *y*-axis refers to relative gene copy number of ORF81 as compared to the sample with 3 μl control siRNA treatment (siRNACo3), the *x*-axis refers to the volume and type of siRNA administered, DNA polymerase (DP) & thymidine kinase (TK) as described in the text. The volume 1 μl is equivalent to 20 μM (0.266 μg/μl), 2 μl is equivalent to 40 μM (0.532 μg/μl), and 3 μl is equivalent to 60 μM (0.798 μg/μl) of siRNA duplexes.](gr2){#fig0010}
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Sequence list (A): primer and probe set targeting the CyHV-3 ORF81 gene (GenBank access number [JQ308818](ncbi-n:JQ308818){#intr0005}, Gene ID: 382929299) used to quantitate CyHV-3 by qPCR. (B): CyHV-3 specific siRNAs target CyHV-3 thymidine kinase (TK) gene (GenBank access number [AB375385](ncbi-n:AB375385){#intr0010}, Gene ID: 241661587) and DNA polymerase (DP) gene (GenBank access number [AY939862](ncbi-n:AY939862){#intr0015}, Gene ID: 61696088). (C): Control siRNAs target Spring Viremia of Carp (SVC) virus, nucleoprotein (N) gene (GenBank access number [NC_002803](ncbi-n:NC_002803){#intr0020}, Gene ID: 921324).

  Name        Targeted gene      Description        Sequence
  ----------- ------------------ ------------------ ----------------------------------------
  A                                                 
   ORF81-FP   ORF81              Forward primer     TGCTGTGTTGCTTGCACTTATYT
   ORF81-RP   ORF81              Reverse primer     TCAAACKAARGACCGCATTTCG
   ORF81-PR   ORF81              Probe              FAM-ATGAAGARGAGTAAACKGCCTGCAACAGA-BHQ1
  B                                                 
   DP         DNA polymerase     Forward siRNA      CCUCUACAACGUGCACUUUTT
   DP         DNA polymerase     Compliment siRNA   AAAGUGCACGUUGUAGAGGTT
   DP         DNA polymerase     Gene target        CCTCTACAACGTGCACTTT
   TK         Thymidine kinase   Forward siRNA      UCGACGAGGGACAGUUCUUTT
   TK         Thymidine kinase   Compliment siRNA   AAGAACUGUCCCUCGUCGATT
  C                                                 
   TK         Thymidine kinase   Gene target        TCGACGAGGGACAGTTCTT
   SVCV-N     Nucleoprotein      Forward siRNA      GGGAUAGCUUCGGACACAATT
   SVCV-N     Nucleoprotein      Compliment siRNA   UUGUGUCCGAAGCUAUCCCTT
   SVCV-N     Nucleoprotein      Gene target        GGGATAGCTTCGGACACAA
